Family history of breast and ovarian cancer and triple negative subtype in hispanic/latina women

Anderson, Kristin; Thompson, Patricia A.; Wertheim, Betsy C.; Martin, Lorena; Komenaka, Ian K.; Bondy, Melissa L.; Daneri-Navarro, ́Adrián; Meza-Montenegro, María Mercedes; Gutierrez-Millan, Luis Enrique; Brewster, Abenaa M.; Madlensky, Lisa; Tobias, Malaika; Martı́nez, Marı́a Elena

doi:10.1186/2193-1801-3-727

Cited by 12 publications

(9 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, family history was defined as positive when at least 1 first- or second-degree relative was affected by breast cancer or ovarian cancer. In a cohort of unselected Hispanic women with TNBC, 56 of 146 (38.4%) reported breast cancer in first- or second-degree relatives [34]. Concordant results were shown in an investigation of 207 unselected TNBC patients with different ethnicities [27].…”

Section: Tnbc and Family Historysupporting

confidence: 48%

Germline Mutations in Triple-Negative Breast Cancer

et al. 2017

View full text Add to dashboard Cite

Triple-negative breast cancer (TNBC) is associated with a poor prognosis and defines a subgroup of patients who do not benefit from endocrine or anti-HER2 therapy. Rather than being a biological entity, TNBC represents a heterogeneous disease, and further subtyping is necessary to establish targeted therapies. Germline mutational status may serve as a robust biomarker predicting therapy response, especially with respect to compounds challenging the DNA repair machinery. Patients with TNBC usually show an early onset of the disease, as well as a positive family history of breast and/or ovarian cancer in more than one third of all cases, which suggests that TNBC is closely associated with a hereditary disease cause. In unselected TNBC cases, the prevalence of pathogenic germline BRCA1/2 mutations is approximately twice as high as in breast cancer overall. Early age at diagnosis and positive family history are strong predictors for an increased BRCA1/2 mutation probability, which is up to 40% when both risk factors are considered. Apart from BRCA1/2, the rarely mutated breast cancer predisposition genes PALB2 and FANCM have been associated with TNBC. This review summarizes the role of germline mutational status in TNBC pathogenesis. Clinical trials addressing BRCA1/2 mutation carriers are discussed.

show abstract

Section: Tnbc and Family Historysupporting

confidence: 48%

Germline Mutations in Triple-Negative Breast Cancer

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The association with family history of breast cancer has been similar across breast cancer subtypes,(3, 6–11, 40) stronger for ER+ breast cancer,(12, 41) and stronger for ER− or TN breast cancer. (13, 14, 42) The strongest evidence comes from a pooled analysis of 12 studies in the Breast Cancer Association Consortium, where an association with family history of breast cancer was present across subtypes, but with a stronger association for basal-like breast cancer. (40)…”

Section: Discussionmentioning

confidence: 99%

Family History of Cancer in Relation to Breast Cancer Subtypes in African American Women

Bethea

Rosenberg

Castro‐Webb

et al. 2016

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Background Evidence on the relation of family history of cancers other than breast cancer to breast cancer risk is conflicting and most studies have not assessed specific breast cancer subtypes. Methods We assessed the relation of first degree family history of breast, prostate, lung, colorectal, ovarian, cervical cancer, and lymphoma or leukemia, to risk of estrogen receptor positive (ER+), ER−, and triple negative breast cancer in data from the African American Breast Cancer Epidemiology and Risk Consortium. Multivariable logistic regression models were used to calculate odds ratios (ORs) and 95% confidence intervals (CIs). Results There were 3,023 ER+ and 1,497 ER− breast cancer cases (including 696 triple negative cases) and 17,420 controls. First degree family history of breast cancer was associated with increased risk of each subtype: OR=1.76 (95% CI 1.57–1.97) for ER+, 1.67 (1.42–1.95) for ER−, and 1.72 (1.38–2.13) for triple negative breast cancer. Family history of cervical cancer was associated with increased risk of ER− (OR=2.39, 95% CI 1.36–4.20), but not ER+ cancer. Family history of both breast and prostate cancer was associated with increased risk of ER+ (3.40, 2.42–4.79) and ER− (2.09, 1.21–3.63) cancer, but family history of both breast and lung cancer was associated only with ER− cancer (2.11, 1.29–3.46). Conclusions A family history of cancers other than breast may influence risk of breast cancer and associations may differ by subtype. Impact Greater surveillance and counseling for additional screening may be warranted for women with a family history of cancer.

show abstract

“…A family history of breast or ovarian cancer is a confirmed prognostic factor for breast cancer, and it has been described that patients with TNBC have a higher proportion of family members with these diagnoses [7,36]. However, few studies have addressed the importance of this factor in the prognosis of breast cancer [37,38].…”

Section: Plos Onementioning

confidence: 99%

Triple-negative breast cancer in Peru: 2000 patients and 15 years of experience

et al. 2020

View full text Add to dashboard Cite

Background Epidemiological studies commonly identify the clinical characteristics and survival outcomes of patients with breast cancer at five years. Our study aims to describe the sociodemographic, clinicopathological characteristics and determine the long-term event-free survival (EFS) and overall survival (OS) of a Peruvian population with triple-negative breast cancer. Methods We reviewed the medical records of new cases treated at a single institution in the period 2000-2014. The survival analysis included patients with stages I-IV. Survival estimates at 10 years were calculated with the Kaplan-Meier method and compared with the Log-rank test. We further used multivariate Cox regression analysis to calculate prognostic factors of recurrence and mortality. Results Among the 2007 patients included, the median age at diagnosis was 49 years (19-95 years). Most patients presented histologic grade III (68.7%), tumor stage II (34.2%), and III (51.0%) at diagnosis. Local and distant relapse was present in 31.9 and 51.4% of the patients, respectively. The most frequent sites of metastasis were the lungs (14.5%), followed by bone (9.7%), brain (9.6%), and liver (7.9%). The median follow-up was 153 months. At 3, 5, and 10 years, the EFS of the population was 55%, 49%, and 41%, respectively, while the OS was 64%, 56%, and 47%, respectively. Moreover, an N3 lymph node status was the most important prognostic factor for both disease relapse (HR: 2.54, 95% CI:

show abstract

Family history of breast and ovarian cancer and triple negative subtype in hispanic/latina women

Cited by 12 publications

References 52 publications

Germline Mutations in Triple-Negative Breast Cancer

Germline Mutations in Triple-Negative Breast Cancer

Family History of Cancer in Relation to Breast Cancer Subtypes in African American Women

Triple-negative breast cancer in Peru: 2000 patients and 15 years of experience

Contact Info

Product

Resources

About